Good evening :)
Place Order
Add to Watchlist

Suven Pharmaceuticals Ltd

SUVENPHAR

Suven Pharmaceuticals Ltd

SUVENPHAR
Health CarePharmaceuticals
MidcapWith a market cap of ₹32,780 cr, stock is ranked 245
Moderate RiskStock is 2.68x as volatile as Nifty
1,287.700.37% (+4.80)
1,287.700.37% (+4.80)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹32,780 cr, stock is ranked 245
Moderate RiskStock is 2.68x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹32,780 cr, stock is ranked 245
Moderate RiskStock is 2.68x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
136.3215.99
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.356.540.51%

Forecast & Ratings

Detailed Forecast 
50%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Suven Pharmaceuticals is engaged in Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 24.09%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.17% to 0.3%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 22.41%, vs industry avg of 15.28%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue378.43900.121,077.691,453.711,386.691,113.261,003.89
Raw Materialssubtract124.52240.24310.32459.46430.08265.88617.19
Power & Fuel Costsubtract18.0638.2444.2059.5573.9348.30
Employee Costsubtract29.6365.1076.23100.48118.25135.92
Selling & Administrative Expensessubtract16.2344.7644.9653.1846.4541.00
Operating & Other expensessubtract17.8460.7091.0165.8497.46154.45
Depreciation/Amortizationsubtract11.5023.5131.6439.1047.9954.6055.33
Interest & Other Itemssubtract2.7923.0711.678.5312.817.456.55
Taxes & Other Itemssubtract48.5987.51105.34213.78148.44105.3984.35
EPS24.9114.2317.8316.1611.809.45
DPS0.002.502.005.006.000.000.00
Payout ratio0.100.140.280.370.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Jun 8PDF
Feb 11PDF
Oct 30PDF
Aug 17PDF
FY 2022

Annual report

PDF

Investor Presentation

May 9PDF
May 9PDF
Feb 8PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

Aug 8PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Suven Pharmaceuticals Ltd109.1715.99
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare SUVENPHAR with any stock or ETF
Compare SUVENPHAR with any stock or ETF
SUVENPHAR
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.10%14.12%2.82%10.70%22.26%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep9.50%10.01%10.14%9.54%9.80%10.70%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Suven Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
DSP ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.9969%1.84%0.26%40/72 (+1)
DSP Healthcare Fund - Growth - Direct Plan

Growth
0.9253%9.80%0.42%2/33 (0)
HSBC Small Cap Fund - Growth - Direct Plan

Growth
0.9208%1.78%0.43%9/109 (+10)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateSep 9, 2022

Special
Special | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Special
Special | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateMay 13, 2022

Interim 2
Interim 2 | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

May 13, 2022

Cash Dividend

Ex DateEx DateFeb 15, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Feb 15, 2022

News & Opinions
Corporate
Suven Pharmaceuticals to conduct EGM

Suven Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 28 November 2024 .Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Suven Pharmaceuticals to convene board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman

Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effective 20 September 2024, as Vaidheesh Annaswamy decides to transition from the Board and becomes the Vice-Chair of Suven's Advisory council.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Suven Pharmaceuticals approves change in Executive Chairperson

The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the following: Vaidheesh Annaswamy (DIN: 01444303) has decided to step down from his role as Executive Chairperson and Director of the Company, effective from close of business hours on 19 September 2024. Approved the appointment of Vivek Sharma (DIN: 08559495) as an Additional Director and Executive Chairman of the Company, as recommended by the Nomination and Remuneration Committee, for a period of five years with effect from 20 September 2024, subject to approval of the shareholders through postal ballot process. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter

Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024 as against Rs 120.59 crore during the previous quarter ended June 2023. Sales declined 33.62% to Rs 230.69 crore in the quarter ended June 2024 as against Rs 347.55 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales230.69347.55 -34 OPM %34.6548.04 - PBDT96.49176.48 -45 PBT83.09163.94 -49 NP60.77120.59 -50 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Suven Pharmaceuticals to hold board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Technical Breakout Stocks: How to trade Torrent Power, Suven Pharma and Granules India on Thursday - Market Summary

3 months agoEconomic Times

Stock exchanges approve Cohance-Suven Pharma merger; NCLT application filed

3 months agoBusiness Standard

L G Balakrishnan & Bros Ltd leads gainers in ‘A’ group

4 months agoBusiness Standard

Suven Pharma Max Health can rally up to 9 Angel One

4 months agoBusiness Standard